Current Capabilities

Protein Analyses

Protein expression

RNA Analyses

Gene expression

DNA Analyses

Mutation or SNP (genetic)

Microbiome Analyses

Abundance and species

Research Use Only Assay

Atopic Dermatitis (AD) vs. Psoriasis (PS)

Confirm the inflammatory signature of clinical trial participants. AD vs. PS differentiates Atopic Dermatitis from Psoriasis.

Atopic Dermatitis (AD) vs. Psoriasis (PS)

Confirm the inflammatory signature of clinical trial participants. AD vs. PS differentiates Atopic Dermatitis from Psoriasis.

Atopic dermatitis (AD) and Psoriasis (PS) exist on a spectrum of inflammation and often exhibit common clinical and histologic features, making them difficult to distinguish visually.1 AD is the most common type of eczema, affecting approximately 10% of the US population, approximately 9.6 million children and 16.5 million adults.2 PS affects more than 3% of the US adult population, nearly 7.5 million US adults.3

AD and PS are immune mediated diseases, Type 2 and Type 3 respectively, characterized by activation of multiple cytokine pathways, barrier disruption, and infiltrating immune cells.

The DermTech® Smart Sticker® enables non-invasive collection of epidermal samples from lesional skin for subsequent gene expression analysis. The AD vs PS assay offers the ability to differentiate the two most common inflammatory diseases using a molecular signature of four key genes.

The ability to distinguish these two inflammatory conditions may provide a valuable tool for biomarker-driven disease differentiation and confirmation in clinical trials and may be utilized for the personalized treatment of AD and PS patients in a clinical trial setting.

For Research Use Only under an IRB Approved Protocol

For Research Use Only under an IRB Approved Protocol

Send us a message

Click the contact us button and drop us a line. We'll be in touch shortly.

Get In Touch

Partner with DermTech today.

  1. Hawerkamp et al. Skin Health Dis. 2022;e99
  2. Silverberg. Dermatol Clin. 2017
  3. Armstrong et al. JAMA Dermatol. 2021